Loading...

GRAIL, Inc.

GRALNASDAQ
Healthcare
Medical - Diagnostics & Research
$34.24
$1.09(3.29%)

GRAIL, Inc. (GRAL) Financial Performance & Income Statement Overview

Access detailed quarterly and annual financial reports for GRAIL, Inc. (GRAL), covering cash flow, earnings, and balance sheets.

Revenue Growth
34.90%
34.90%
Operating Income Growth
-44.46%
44.46%
Net Income Growth
-38.30%
38.30%
Operating Cash Flow Growth
3.13%
3.13%
Operating Margin
-471.32%
471.32%
Gross Margin
-5.43%
5.43%
Net Profit Margin
-329.86%
329.86%
ROE
-18.04%
18.04%
ROIC
-24.05%
24.05%

GRAIL, Inc. (GRAL) Income Statement & Financial Overview

Analyze GRAIL, Inc.’s GRAL earnings with segmented quarterly and yearly financial statement figures.

MetricQ4 2024Q3 2024Q2 2024Q1 2024
Revenue$38.25M$28.65M$31.97M$26.72M
Cost of Revenue$54.22M$50.88M$49.88M$48.63M
Gross Profit-$15.97M-$22.23M-$17.91M-$21.91M
Gross Profit Ratio-$0.42-$0.78-$0.56-$0.82
R&D Expenses$48.33M$78.23M$94.20M$101.63M
SG&A Expenses$72.64M$83.04M$108.25M$103.89M
Operating Expenses$121.66M$161.27M$1.62B$205.51M
Total Costs & Expenses$175.19M$212.16M$1.67B$254.14M
Interest Income$9.37M$11.66M$2.81M$2.90M
Interest Expense$0.00$0.00$0.00$0.00
Depreciation & Amortization$39.44M$39.23M$39.39M$40.00M
EBITDA-$97.50M-$144.28M-$180.97M-$187.43M
EBITDA Ratio-$2.55-$5.04-$5.66-$7.01
Operating Income-$136.94M-$183.51M-$1.64B-$227.42M
Operating Income Ratio-$3.58-$6.40-$51.34-$8.51
Other Income/Expenses (Net)$9.94M$11.10M$2.81M$2.94M
Income Before Tax-$126.99M-$172.41M-$1.64B-$224.48M
Income Before Tax Ratio-$3.32-$6.02-$51.25-$8.40
Income Tax Expense-$29.93M-$46.72M-$53.14M-$5.57M
Net Income-$97.07M-$125.69M-$1.59B-$218.91M
Net Income Ratio-$2.54-$4.39-$49.59-$8.19
EPS-$2.89-$3.94-$51.06-$7.05
Diluted EPS-$2.89-$3.94-$51.06-$7.05
Weighted Avg Shares Outstanding$33.89M$31.88M$31.05M$31.05M
Weighted Avg Shares Outstanding (Diluted)$33.89M$31.88M$31.05M$31.05M

The company's financials show resilient growth, with revenue advancing from $26.72M in Q1 2024 to $38.25M in Q4 2024. Gross profit remained healthy with margins at -42% in Q4 2024 compared to -82% in Q1 2024. Operating income hit -$136.94M last quarter, sustaining a consistent -358% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$97.50M. Net income rose to -$97.07M, while earnings per share reached -$2.89. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;